Are there specific patient populations who are at higher risk for adverse effects from ixekizumab?

Featuring Joel Gelfand, MD, MSCE, FAAD | Penn MedicineDirector, Psoriasis and Phototherapy Treatment CenterDirector, Center for Clinical Sciences in DermatologyPhiladelphia, Pennsylvania | Published November 01, 2024